Compare · ATLN vs WAT
ATLN vs WAT
Side-by-side comparison of Atlantic International Corp. (ATLN) and Waters Corporation (WAT): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both ATLN and WAT operate in Biotechnology: Laboratory Analytical Instruments (Industrials), so they compete in similar markets.
- WAT is the larger of the two at $36.64B, about 500.8x ATLN ($73.2M).
- Over the past year, ATLN is down 59.7% and WAT is up 22.7% - WAT leads by 82.4 points.
- ATLN has been more active in the news (11 items in the past 4 weeks vs 8 for WAT).
- WAT has more recent analyst coverage (25 ratings vs 0 for ATLN).
- Company
- Atlantic International Corp.
- Waters Corporation
- Price
- $0.90-5.48%
- $373.03-0.90%
- Market cap
- $73.2M
- $36.64B
- 1M return
- -38.55%
- +2.71%
- 1Y return
- -59.67%
- +22.70%
- Industry
- Biotechnology: Laboratory Analytical Instruments
- Biotechnology: Laboratory Analytical Instruments
- Exchange
- NASDAQ
- NYSE
- IPO
- 2024
- 1995
- News (4w)
- 11
- 8
- Recent ratings
- 0
- 25
Waters Corporation
Waters Corporation, a specialty measurement company, provides analytical workflow solutions in Asia, the Americas, and Europe. It operates through two segments, Waters and TA. The company designs, manufactures, sells, and services high and ultra-performance liquid chromatography, as well as mass spectrometry (MS) technology systems and support products, including chromatography columns, other consumable products, and post-warranty service plans. It also designs, manufactures, sells, and services thermal analysis, rheometry, and calorimetry instruments; and develops and supplies software-based products that interface with its instruments, as well as other manufacturers' instruments. Its MS technology instruments are used in drug discovery and development comprising clinical trial testing, the analysis of proteins in disease processes, nutritional safety analysis, and environmental testing. The company's offers thermal analysis, rheometry, and calorimetry instruments for use in predicting the suitability and stability of fine chemicals, pharmaceuticals, water, polymers, metals, and viscous liquids for various industrial, consumer good, and healthcare products, as well as for life science research. Its products are used by pharmaceutical, biochemical, industrial, nutritional safety, environmental, academic, and governmental customers working in research and development, quality assurance, and other laboratory applications. The company has a collaboration with Genovis AB to develop and market biopharmaceutical characterization workflows based on the its BioAccord LC-MS System, Andrew+ pipetting robot and Genovis SmartEnzymes. Waters Corporation was founded in 1958 and is headquartered in Milford, Massachusetts.
Latest ATLN
- Circle8 Awarded Two $20 Million Dutch Public Sector Contract Extensions, Demonstrating Positive Commercial Momentum Across the Public Sector
- Chairman & CEO Franke Guus Paul Wilhelm sold $308,783 worth of shares (308,783 units at $1.00), decreasing direct ownership by 2% to 12,207,287 units (SEC Form 4)
- SEC Form 424B3 filed by Atlantic International Corp.
- Atlantic International's Circle8 Awarded $175 Million Contract Extension From the Dutch Ministry Of Infrastructure (Rijkswaterstaat)
- Atlantic International Relaunches As Circle8, Reflecting Its Evolution Into A Global Technology and Workforce Solutions Platform
- Atlantic International Corp. filed SEC Form 8-K: Results of Operations and Financial Condition, Regulation FD Disclosure, Other Events, Financial Statements and Exhibits
- Atlantic International Corp Regains Compliance With Nasdaq Listing Requirements
- SEC Form 424B3 filed by Atlantic International Corp.
- Atlantic International’s Circle8 Secures Minimum $52 Million Government Contract Award
- Atlantic International Reports Record First Quarter 2026 Revenue of $249.9 Million
Latest WAT
- RBC Capital Mkts initiated coverage on Waters with a new price target
- Director Knight Heather was granted 63 shares, increasing direct ownership by 5% to 1,281 units (SEC Form 4)
- Director Jiang Wei was granted 67 shares, increasing direct ownership by 2% to 3,573 units (SEC Form 4)
- Waters Corporation Schedules Second Quarter 2026 Earnings Conference Call
- Bernstein resumed coverage on Waters with a new price target
- SVP Waters Analytical Sciences Carpio Robert L Iii covered exercise/tax liability with 189 shares, decreasing direct ownership by 5% to 3,426 units (SEC Form 4) (for withholding tax)
- SEC Form 11-K filed by Waters Corporation
- IMU Biosciences Selects Waters to Advance Breakthrough AI Immune Mapping Platform to Transform Early Diagnosis, Monitoring, and Precision Medicine
- Piper Sandler initiated coverage on Waters with a new price target
- Waters Launches Coin Cell Differential Scanning Calorimeter (DSC) to Advance Battery Safety with Integrated Thermal, Evolved Gas, and Electrochemical Analysis